Recent News

• 09.11.2025 - Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
• 09.10.2025 - Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
• 09.04.2025 - Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.03.2025 - Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
• 09.02.2025 - Royalty Pharma and Zenas Biopharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
• 08.25.2025 - Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
• 08.13.2025 - Henry Fernandez Steps Down from Royalty Pharma’s Board of Directors

Recent Filings

• 09.03.2025 - 424B2 Prospectus [Rule 424(b)(2)]
• 09.03.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 09.02.2025 - 424B2 Prospectus [Rule 424(b)(2)]
• 09.02.2025 - POSASR Post-effective Amendment to an automatic shelf registration statement
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 144 Report of proposed sale of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities